Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 2/20 | 0.69 |
| ▸ | CDC25B | P30305 | 1/20 | 0.69 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.68 |
| ▸ | APAF1 | O14727 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 3/20 | 0.49 |
| ▸ | CES1 | P23141 | 3/20 | 0.49 |
| ▸ | SOAT1 | P35610 | 8/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5595746 | 1.00 | PTPRC (0.69) | PTPRCCDC25BPTPN1APAF1ALDH1A1 | |
| SCHEMBL4294847 | 0.98 | PTPRC (0.71) | PTPRCCDC25BPTPN1APAF1ALDH1A1 | |
| Naphthoquinone SCHEMBL8525306 | 0.94 | PTPRC (0.61) | PTPRCCDC25BPTPN1APAF1ALDH1A1 | |
| SCHEMBL9628579 | 0.88 | CDC25B (0.56) | PTPRCCDC25BPTPN1APAF1ALDH1A1 | |
| SCHEMBL11247136 | 0.88 | CDC25B (0.56) | PTPRCCDC25BPTPN1APAF1ALDH1A1 | |
| SCHEMBL9713908 | 0.88 | CDC25B (0.56) | PTPRCCDC25BPTPN1APAF1ALDH1A1 | |
| SCHEMBL7718305 | 0.88 | PTPRC (0.51) | PTPRCCDC25BPTPN1APAF1ALDH1A1 | |
| SCHEMBL7718306 | 0.88 | PTPRC (0.51) | PTPRCCDC25BPTPN1APAF1ALDH1A1 | |
| SCHEMBL9444193 | 0.86 | CDC25B (0.57) | PTPRCCDC25BPTPN1APAF1ALDH1A1 | |
| SCHEMBL13611359 | 0.86 | PTPN1 (0.69) | PTPRCCDC25BPTPN1ALDH1A1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | PROGEN PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CELLGATE, INC. | 2008-08-14 | — | — | US | disclosed |
| US-7253207-B2 | Quinones as disease therapies | CELLGATE, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253207-B2 | Quinones as disease therapies | CELLGATE, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253207-B2 | Quinones as disease therapies | CELLGATE, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20050010060-A1 | Novel quinones as disease therapies | SLIL BIOMEDICAL CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010060-A1 | Novel quinones as disease therapies | NQO1, NDUFV2, SDHB | PTPRC 1827/4885CDC25B 1302/4885PTPN1 3247/4885 |
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CTSB, KLK3, FOLH1 | PTPRC 1472/4885CDC25B 190/4885PTPN1 3701/4885 |
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CTSB, CTSL, CTSV | PTPRC 1675/4885CDC25B 511/4885PTPN1 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.